Senesco Tech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eloxx Pharmaceuticals Inc (ELOX)
The Eloxx Pharmaceuticals share price today is 13.320, view NASDAQ ELOX stock exchange data. Track the latest Eloxx Pharmaceuticals share price with real-time updates on ELOX stock performance including market cap, day range, 52-week range and dividend yield. Access ELOX charts, earnings dates and analyst estimates to support your investment decisions.
NASDAQ
Currency in USD
13.320
-0.380(-2.77%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.180
14.110
52 wk Range
13.180
23.400
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.18014.110
52 wk Range
13.18023.400
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockELOX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
38.250
Upside
+187.16%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Senesco Tech receives Investment Bank Analyst Rating Update- Investing.com
Pro
Form 8K Eloxx Pharmaceuticals Inc For: 11 August- Investing.com
- Senesco Tech receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Senesco Tech receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Eloxx doses first patients in Alport syndrome trial- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 38.250
(+187.16% Upside)
Earnings
Latest Release
12-08-2026
EPS / Forecast
-0.66 / --
Revenue / Forecast
-- / --
Compare ELOX to Peers and Sector
Metrics to compare | ELOX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELOXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.1x | −2.2x | −0.3x | |
PEG Ratio | - | −0.02 | 0.00 | |
Price/Book | 1.2x | 1.7x | 2.6x | |
Price / LTM Sales | - | 2.6x | 2.9x | |
Upside (Analyst Target) | 179.2% | 207.0% | 64.3% | |
Fair Value Upside | Unlock | 7.7% | 9.9% | Unlock |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Eloxx Pharmaceuticals (ELOX) Share Price Today?
The Eloxx Pharmaceuticals share price today is 13.320.
What is the current Eloxx Pharmaceuticals (ELOX) share price and day range?
As of 16-10-2026, the Eloxx Pharmaceuticals share price is 13.320, with a previous close of 13.700. The share price has ranged from 13.180 to 14.110 today, while the 52-week range spans from 13.180 to 23.400.
What Is the Eloxx Pharmaceuticals Market Cap?
As of today, Eloxx Pharmaceuticals market cap is 53.770M.
What Is the Eloxx Pharmaceuticals (ELOX) Share Price Target?
The average 12-month share price target for Eloxx Pharmaceuticals is 38.250, with a high estimate of 43 and a low estimate of 32. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +187.16% Upside potential.
What Is Eloxx Pharmaceuticals's Earnings Per Share (TTM)?
The Eloxx Pharmaceuticals EPS (TTM) is -2.84.
When Is the Next Eloxx Pharmaceuticals Earnings Date?
Eloxx Pharmaceuticals will release its next earnings report on 11-11-2026.
From a Technical Analysis Perspective, Is ELOX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Eloxx Pharmaceuticals Trade On?
Eloxx Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Eloxx Pharmaceuticals?
The stock symbol for Eloxx Pharmaceuticals is "ELOX."
How Many Times Has Eloxx Pharmaceuticals Stock Split?
Eloxx Pharmaceuticals has split 4 times.
How Many Employees Does Eloxx Pharmaceuticals Have?
Eloxx Pharmaceuticals has 10 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.